Zynex Competitors

BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 29.6% of Zynex shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Comparatively, 50.5% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and Zynex's net margins, return on equity and return on assets.

Volatility & Risk

BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for BioLife Solutions and Zynex, as reported by MarketBeat.com.

BioLife Solutions presently has a consensus target price of $46.6667, suggesting a potential upside of 49.05%. Zynex has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. Given BioLife Solutions' stronger consensus rating and higher probable upside, equities analysts clearly believe BioLife Solutions is more favorable than Zynex.

Earnings and Valuation

This table compares BioLife Solutions and Zynex's gross revenue, earnings per share and valuation.

Zynex has higher revenue and earnings than BioLife Solutions. Zynex is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

Zynex beats BioLife Solutions on 8 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Volatility & Risk

Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Natus Medical and Zynex, as provided by MarketBeat.

Zynex has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. Given Zynex's stronger consensus rating and higher possible upside, analysts clearly believe Zynex is more favorable than Natus Medical.

Profitability

This table compares Natus Medical and Zynex's net margins, return on equity and return on assets.

Institutional and Insider Ownership

89.7% of Natus Medical shares are held by institutional investors. Comparatively, 29.6% of Zynex shares are held by institutional investors. 1.5% of Natus Medical shares are held by company insiders. Comparatively, 50.5% of Zynex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Natus Medical and Zynex's revenue, earnings per share (EPS) and valuation.

Zynex has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Summary

Zynex beats Natus Medical on 10 of the 14 factors compared between the two stocks.

Zynex (NASDAQ:ZYXI) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares Zynex and AxoGen's revenue, earnings per share and valuation.

Zynex has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

29.6% of Zynex shares are owned by institutional investors. Comparatively, 78.4% of AxoGen shares are owned by institutional investors. 50.5% of Zynex shares are owned by insiders. Comparatively, 6.9% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Zynex and AxoGen's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zynex and AxoGen, as provided by MarketBeat.

Zynex presently has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. AxoGen has a consensus target price of $23.75, suggesting a potential upside of 33.88%. Given Zynex's higher probable upside, analysts clearly believe Zynex is more favorable than AxoGen.

Risk and Volatility

Zynex has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Summary

Zynex beats AxoGen on 9 of the 14 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares TransMedics Group and Zynex's gross revenue, earnings per share (EPS) and valuation.

Zynex has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 29.6% of Zynex shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 50.5% of Zynex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares TransMedics Group and Zynex's net margins, return on equity and return on assets.

Risk & Volatility

TransMedics Group has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for TransMedics Group and Zynex, as reported by MarketBeat.

TransMedics Group presently has a consensus price target of $44.20, indicating a potential upside of 79.82%. Zynex has a consensus price target of $21.6250, indicating a potential upside of 46.81%. Given TransMedics Group's stronger consensus rating and higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than Zynex.

Summary

Zynex beats TransMedics Group on 8 of the 14 factors compared between the two stocks.

ViewRay (NASDAQ:VRAY) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares ViewRay and Zynex's gross revenue, earnings per share and valuation.

Zynex has lower revenue, but higher earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for ViewRay and Zynex, as provided by MarketBeat.com.

ViewRay currently has a consensus target price of $4.50, suggesting a potential upside of 13.92%. Zynex has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. Given Zynex's higher probable upside, analysts plainly believe Zynex is more favorable than ViewRay.

Profitability

This table compares ViewRay and Zynex's net margins, return on equity and return on assets.

Insider and Institutional Ownership

83.0% of ViewRay shares are held by institutional investors. Comparatively, 29.6% of Zynex shares are held by institutional investors. 15.5% of ViewRay shares are held by insiders. Comparatively, 50.5% of Zynex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

ViewRay has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Summary

Zynex beats ViewRay on 9 of the 14 factors compared between the two stocks.

Zynex (NASDAQ:ZYXI) and Cutera (NASDAQ:CUTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Zynex and Cutera's net margins, return on equity and return on assets.

Insider and Institutional Ownership

29.6% of Zynex shares are held by institutional investors. Comparatively, 87.8% of Cutera shares are held by institutional investors. 50.5% of Zynex shares are held by company insiders. Comparatively, 2.3% of Cutera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zynex and Cutera, as reported by MarketBeat.com.

Zynex currently has a consensus price target of $21.6250, suggesting a potential upside of 46.81%. Cutera has a consensus price target of $30.6667, suggesting a potential upside of 10.55%. Given Zynex's higher probable upside, equities research analysts clearly believe Zynex is more favorable than Cutera.

Volatility and Risk

Zynex has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Cutera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Earnings and Valuation

This table compares Zynex and Cutera's gross revenue, earnings per share (EPS) and valuation.

Zynex has higher earnings, but lower revenue than Cutera. Cutera is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Summary

Zynex beats Cutera on 9 of the 14 factors compared between the two stocks.